Literature DB >> 21450940

Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation.

Chiara Villa1, Maria Stefania Lagonigro, Flavia Magri, Maria Koziak, Marie-Lise Jaffrain-Rea, Raja Brauner, Jerome Bouligand, Marie Pierre Junier, Federico Di Rocco, Christian Sainte-Rose, Albert Beckers, François Xavier Roux, Adrian F Daly, Luca Chiovato.   

Abstract

Mutations of the aryl hydrocarbon receptor interacting protein (AIP) gene are associated with pituitary adenomas that usually occur as familial isolated pituitary adenomas (FIPA). Detailed pathological and tumor genetic data on AIP mutation-related pituitary adenomas are not sufficient. Non-identical twin females presented as adolescents to the emergency department with severe progressive headache caused by large pituitary macroadenomas require emergency neurosurgery; one patient had incipient pituitary apoplexy. Post-surgically, the patients were found to have silent somatotrope adenomas on pathological examination. Furthermore, the light microscopic, immunohistochemical, and electron microscopic studies demonstrated tumors of virtually identical characteristics. The adenomas were accompanied by multiple areas of pituitary hyperplasia, which stained positively for GH, indicating somatotrope hyperplasia. Genetic analyses of the FIPA kindred revealed a novel E216X mutation of the AIP gene, which was present in both the affected patients and the unaffected father. Molecular analysis of surgical specimens revealed loss of heterozygosity (LOH) in the adenoma but showed that LOH was not present in the hyperplastic pituitary tissue from either patient. AIP immunostaining confirmed normal staining in the hyperplastic tissue and decreased staining in the adenoma in the tumors from both patients. These results demonstrate that patients with AIP germline mutation can present with silent somatotrope pituitary adenomas. The finding of somatotrope hyperplasia unaccompanied by AIP LOH suggests that LOH at the AIP locus might be a late event in a potential progression from hyperplastic to adenomatous tissue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450940     DOI: 10.1530/ERC-11-0059

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  26 in total

1.  Familial pituitary apoplexy as the only presentation of a novel AIP mutation.

Authors:  Paraskevi Xekouki; Spyridon A Mastroyiannis; Dimitrios Avgeropoulos; Maria de la Luz Sierra; Giampaolo Trivellin; Evgenia A Gourgari; Charalampos Lyssikatos; Martha Quezado; Nicholas Patronas; Christina Kanaka-Gantenbein; George P Chrousos; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2013-09-11       Impact factor: 5.678

Review 2.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.

Authors:  Paraskevi Xekouki; Eva Szarek; Petra Bullova; Alessio Giubellino; Martha Quezado; Spyridon A Mastroyannis; Panagiotis Mastorakos; Christopher A Wassif; Margarita Raygada; Nadia Rentia; Louis Dye; Antony Cougnoux; Deloris Koziol; Maria de La Luz Sierra; Charalampos Lyssikatos; Elena Belyavskaya; Carl Malchoff; Jessica Moline; Charis Eng; Louis James Maher; Karel Pacak; Maya Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-02-19       Impact factor: 5.958

Review 4.  Genetic mutations in sporadic pituitary adenomas--what to screen for?

Authors:  Anne-Lise Lecoq; Peter Kamenický; Anne Guiochon-Mantel; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2014-10-28       Impact factor: 43.330

5.  X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

Authors:  Albert Beckers; Maya Beth Lodish; Giampaolo Trivellin; Liliya Rostomyan; Misu Lee; Fabio R Faucz; Bo Yuan; Catherine S Choong; Jean-Hubert Caberg; Elisa Verrua; Luciana Ansaneli Naves; Tim D Cheetham; Jacques Young; Philippe A Lysy; Patrick Petrossians; Andrew Cotterill; Nalini Samir Shah; Daniel Metzger; Emilie Castermans; Maria Rosaria Ambrosio; Chiara Villa; Natalia Strebkova; Nadia Mazerkina; Stéphan Gaillard; Gustavo Barcelos Barra; Luis Augusto Casulari; Sebastian J Neggers; Roberto Salvatori; Marie-Lise Jaffrain-Rea; Margaret Zacharin; Beatriz Lecumberri Santamaria; Sabina Zacharieva; Ee Mun Lim; Giovanna Mantovani; Maria Chaira Zatelli; Michael T Collins; Jean-François Bonneville; Martha Quezado; Prashant Chittiboina; Edward H Oldfield; Vincent Bours; Pengfei Liu; Wouter W de Herder; Natalia Pellegata; James R Lupski; Adrian F Daly; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2015-02-24       Impact factor: 5.678

Review 6.  The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.

Authors:  Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2018-10-01       Impact factor: 2.936

Review 7.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

9.  SNPs in the aryl hydrocarbon receptor-interacting protein gene associated with sporadic non-functioning pituitary adenoma.

Authors:  Yeshuai Hu; Jun Yang; Yongkai Chang; Shunchang Ma; Jianfa Qi
Journal:  Exp Ther Med       Date:  2016-01-18       Impact factor: 2.447

Review 10.  Hyperplasia in glands with hormone excess.

Authors:  Stephen J Marx
Journal:  Endocr Relat Cancer       Date:  2015-09-25       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.